Company / Cash & Equivalents
Celularity Inc Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$6.2M
FY2025
5-year range
$227.0K / $37.2M
FY2021-FY2025
Trend
+736.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +737% YoY in FY2025, a notable deviation from the 4-year average annual change of +200%.
Based on SEC 10-K filings.
$6M in FY2025 with a 3-year CAGR of -23.8%.
Improved from $227,000 to $6M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -23.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -23.8%, indicating a declining trend.
- In FY2025, cash & equivalents increased 736.7% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.2M | +736.7% |
| FY2024 | $738.0K | +225.1% |
| FY2023 | $227.0K | -98.4% |
| FY2022 | $14.0M | -62.5% |
| FY2021 | $37.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026